Arne Echterhof
Overview
Explore the profile of Arne Echterhof including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
2
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Echterhof A, Dharmaraj T, Blankenberg P, Hajfathalian M, Blankenberg F, Sacher J, et al.
bioRxiv
. 2025 Feb;
PMID: 39975350
Bacteriophages, viruses that selectively infect bacteria, are increasingly explored as potential therapies to combat antibiotic-resistant infections. Effective phage purification is vital for therapeutic use, particularly to reduce endotoxin (lipopolysaccharide, LPS)...
2.
Whole-body Bacteriophage Distribution Characterized by a Physiologically based Pharmacokinetic Model
Echterhof A, Dharmaraj T, Blankenberg P, Targ B, Bollyky P, Smith N, et al.
bioRxiv
. 2025 Feb;
PMID: 39975270
In 2019 there were over 2.8 million cases of antibiotic-resistant bacterial infection in the US with gram negative organisms having up to a 6% rate of mortality. Bacteriophage (phage) therapy...
3.
Kim M, Chen Q, Echterhof A, Pennetzdorfer N, McBride R, Banaei N, et al.
Nat Commun
. 2024 Nov;
15(1):9987.
PMID: 39609398
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application is mainly limited to personalized therapy due to the narrow host range of individual phages....
4.
Echterhof A, Dharmaraj T, Khosravi A, McBride R, Miesel L, Chia J, et al.
JCI Insight
. 2024 Oct;
9(20).
PMID: 39435664
With the increasing prevalence of antimicrobial-resistant bacterial infections, there is interest in using bacteriophages (phages) to treat such infections. However, the factors that govern bacteriophage pharmacokinetics in vivo remain poorly...
5.
Khosravi A, Chen Q, Echterhof A, Koff J, Bollyky P
Lung
. 2024 May;
202(3):223-232.
PMID: 38772946
We are entering the post-antibiotic era. Antimicrobial resistance (AMR) is a critical problem in chronic lung infections resulting in progressive respiratory failure and increased mortality. In the absence of emerging...
6.
Lin Y, Dharmaraj T, Chen Q, Echterhof A, Manasherob R, Zhang L, et al.
bioRxiv
. 2024 May;
PMID: 38766200
Lytic bacteriophages, viruses that lyse (kill) bacteria, hold great promise for treating infections, including wound infections caused by antimicrobial-resistant However, the optimal dosing and delivery strategies for phage therapy remain...
7.
Echterhof A, Dharmaraj T, McBride R, Berry J, Hopkins M, Selvakumar H, et al.
bioRxiv
. 2024 Feb;
PMID: 38328123
With the increasing prevalence of antimicrobial-resistant bacterial infections, there is great interest in using lytic bacteriophages (phages) to treat such infections. However, the factors that govern bacteriophage pharmacokinetics remain poorly...